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As the global burden of diabetes is increasing there is a corresponding increase 
in the complications associated with the same. Diabetic retinopathy is a sight threat-
ening complication of diabetes mellitus which was considered to be a microvascu-
lopathy. Recent evidence however, has brought to light that inflammation may be a 
key player in the pathogenesis of this condition. Levels of inflammatory mediators 
like Hypoxia inducible factor, TNF-α, IL-6 and IL-1B amongst others have been 
noted to be elevated in the diabetic vitreous gel. The concept of the neurovascular 
unit better explains the changes that take place resulting in the breakdown of the 
blood retinal barriers and how these inflammatory mediators affect the morphol-
ogy of the retina at a cellular level. Glial cells form a key instrument of this neuro-
vascular structure and are also the cells from where the inflammatory response is 
initiated. Understanding of the pathogenesis of diabetic retinopathy will help us in 
finding targeted therapies which may provide long term benefits and possible cure. 
Few anti-inflammatory medications have shown promise albeit in a small clinical 
or experimental laboratory setting. However, future research may lead to better 
understanding of the disease and a better pharmacological intervention.
Keywords: pathogenesis of diabetic retinopathy, glial cells in diabetic retinopathy, 
retina inflammation, steroids, cytokines
1. Introduction
In the past few years, unhealthy lifestyle coupled with obesity has led to a 
rampant increase in the global burden of diabetes mellitus. As per WHO the global 
prevalence of the condition was 422 million in the year (2014) with 8.5% of adults 
aged more than 18 years suffering from this condition. Approximately 1.6 million 
deaths yearly are supposed to be caused by diabetes alone, this number excludes 
the mortality associated with cardiovascular events, renal disease and tuberculosis 
secondary to chronic hyperglycemia [1]. The global burden of diabetes is expected 
to swell to 642 million adults by the year 2040 with 75% of the affected individuals 
belonging to low and middle income countries. Diabetic retinopathy affects 1 in 3 
adults with diabetes and is one of the major causes of blindness in the working-age 
population [2].
Diabetic retinopathy (DR) is a major microvascular complication of diabetes 
and it is categorised into a non-proliferative stage (NPDR) or proliferative stage 
(PDR) depending on the presence of retinal microvascular changes. The non-
proliferative stage is characterised by the presence of microaneurysms, cotton wool 
spots, vascular tortuosity, retinal haemorrhage and lipid exudation while in the 
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proliferative stage aberrant new blood vessels develop which are fragile and can 
extend into the posterior cortical vitreous [3]. Another important element in the 
vast conundrum of DR is diabetic macular edema (DME). It can occur across all 
levels of DR changes and compromises central vision. DME is the most common 
cause of diminished vision in an individual with DR [4].
2. The neurovascular unit in diabetic retinopathy
In recent years a concept of neurovascular unit in diabetic retinopathy has 
emerged. This is based on the findings that neurodegeneration is one of the 
earliest changes in a case of diabetic retinopathy. Indeed, a reduction in oscilla-
tory potential in the electroretinogram is the first measurable change in retinal 
function, being recorded even in cases wherein there is no clinical change 
suggestive of DR. This indicates that neurodegeneration precedes microvascular 
abnormalities [5].
The retinal neurovascular unit includes the physical and biochemical interac-
tions amongst the neurons, the vascular beds and the supporting cells of the retinal 
framework. The neural unit includes the ganglion cells and the glial cells while the 
vascular component of the unit is made up of the endothelial cells and the pericytes. 
The neurovascular unit reflects the inter-dependance of the vascular barrier and 
blood flow regulation on the glial cells, pericytes and neurons as well as their recip-
rocal dependance on vascular support. Together with the neurovascular unit the 
retinal pigment epithelium contributes to the formation of the blood retinal barrier 
[6]. The inner blood retinal barrier (iBRB) encompasses the endothelial cells of 
the retinal microvasculature which are covered by astrocytes, pericytes and muller 
cell end-feet. It regulates the transport across the retinal capillaries and maintain 
the micro-environment of the inner retina. The outer blood retinal barrier (oBRB) 
comprises the tight junctions of the neighbouring RPE cells and it serves as a filter 
for nutrients and solutes from the blood [7].
3. Histopathological changes in diabetic retinopathy
Diabetic retinopathy has been traditionally described as a microvasculopathy, 
however newer evidence has suggested that inflammation may provide a substantial 
role in the histopathological changes that are noted in the disease.
3.1 Microvascular changes
Retinal ischemia is the initiator that propels the plethora of changes that occur 
in DR. In the initial stages, prior to even the development of visually significant 
vascular alterations, there is a disruption of vascular auto-regulation which leads to 
oxygen and nutrient deprivation in the inner retinal layers [8].
Retinal vascular basement membrane thickening is present in the early stages 
of the disease and is mediated by hyperglycemia. Impaired sugar levels lead to an 
up-regulation of extracellular matrix proteins, collagen and fibronectin [9]. This 
thickening of the basement membrane may lead to an impairment in cell to cell 
communication between the endothelium, pericytes, glial cells and the retinal 
immune cells, ultimately leading to a loss of function [10]. Loss of pericytes leads to 
a weakening of the capillary wall; this ultimately results in the development of areas 
of out-pouching labelled as microaneurysms (MA), which are amongst the first 
clinically detectable signs of DR [11].
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A progressive occlusion of the retinal capillaries is noted on histopathological 
evaluation of post-mortem specimens. Stitt et al. [12] evaluated trypsin digest 
preparations of these capillaries and noted them to be acellular tubes of naked 
basement membrane without endothelial cells. The loss of endothelial cells can be 
attributed to pericyte death which ultimately culminates into breakdown of the 
inner blood retinal barrier.
The breakdown of the inner blood retinal barrier would lead accumulation of 
fluid and exudates in the retinal layers contributing to diabetic macular edema 
(DME). Fluid exuding out from the superficial capillary plexus leads to accumula-
tion of fluid in the inner nuclear layer while that exuding out from the deep capil-
lary plexus is believed to collect in the outer plexiform layer. Cystoid spaces noted 
in the macula appear due to liquefaction and necrosis of the muller cells and the 
production of prostaglandins and inflammatory cytokines [13].
3.2 Neuroglial changes
The muller cells, astrocytes and microglial cells are present in close vicinity of 
the retinal blood vessels and help to maintain retina homeostasis. Muller cells play 
a central role in the retinal metabolism and hence are susceptible to the metabolic 
alterations of diabetes. An increased production of glial fibrillary acidic protein 
(GFAP) by the muller cells is noted in the early part of the disease, which plays a key 
role in gliosis. This is indicative of a state of glial hypertrophy [14].
Microglial cells are the resident inflammatory cells of the retina which get acti-
vated in DR. In the early stages of mild DR a hypertrophy of the microglia is noted 
and the cells are settled along the retinal plexiform layers. When the DR progresses 
into a proliferative stage the microglial cells are found to be extensively distributed 
in areas of retinal ischemia and neovascularisation [15]. A strong tendency of the 
microglial cells to invade the outer retinal layers is also noted in prolonged DR [16].
3.3 Neuronal changes
Overt degeneration of retinal neurons during diabetes is a concept that was first 
described in the 1960s in post-mortem patient samples. By the late 1990s experi-
mental evidence reinforced this finding by demonstrating that depletion of some 
neuronal populations occurred in diabetic rodent models, possibly even prior to 
appearance of obvious microvascular lesions. Apoptosis of the retinal ganglion cells 
(RGCs) is histologically noted in diabetic retinas. This also accounts for the dimin-
ished thickness of the retinal nerve fibre layer on optical coherence tomography 
(OCT). It is believed that hyperglycemia induces a down-regulation of neuronal 
growth factors thereby contributing to programmed cell death [17].
3.4 Immune cell activation
Histological evaluation of blood vessels, early in the course of DR, have shown 
increased interaction between leukocytes and endothelial cells. This phenomenon 
called leukostasis is characterised by an adherence of monocytes and neutrophils to 
the endothelial lining of the blood vessels. This leads to blockage of the thin retinal 
capillaries and areas of retinal non-perfusion [18].
3.5 Retinal pigment epithelium and choroid
The changes are not only localised to the inner retinal layers but also extend 
to the RPE and the choroid compromising the outer blood retinal barrier. RPE 
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dysfunction and leakage from the choriocapillaris is noted leading to outer retinal 
edema and impaired clearance of fluid [19].
Choroidal atrophy has been noted in cases of long standing DR, with a dimin-
ished choroidal thickness noted on OCT evaluation. This thinning of the choroid 
have been linked to HbA1c levels and may lead to choroidal neovascular membranes 
or intra-choroidal microvascular abnormalities [20].
4. Inflammation in DR
4.1 What is inflammation?
Inflammation is non-specific response of the the body to injury or stress 
which includes a variety of molecular and cellular mediators. Tissue stress may 
lead to de-inhibition of the transcription factor nuclear factor kappa beta (NF-
κB) which stimulates the production of acute phase proteins, pro-inflammatory 
cytokines and chemokines such as TNF-α, IL-6 and IL-1B amongst others. These 
pro-inflammatory mediators play a major role in the unfolding of the inflamma-
tory processes with recruitment and activation of monocytes and leukocytes. 
Inflammation usually resolves spontaneously in a coordinated manner, however 
when this fails to happen the beneficial effect of inflammation is lost and conse-
quences ensue.
4.2 Inflammation in pathogenesis of diabetic retinopathy
If we consider diabetic retinopathy to be a disease mediated via the inflamma-
tory pathway then anti-inflammatory medications should provide some degree of 
safety. This was noted in 1964 by Powell and Field who reported that patients with 
rheumatoid arthritis on high dose aspirin therapy tended to have a less severe form 
of DR [21]. Histological features of DR were less commonly noted in dogs wherein 
aspirin was initiated in a dose of 20-25 mg/kg/day shortly after the diagnosis of 
diabetes mellitus and continued for a period of 5 years [22].
Increased concentrations of inflammatory cytokines such as IL-1, IL-6, IL-8, 
TNF-α and MCP-1—have been reported in ocular tissues from non-proliferative 
DR (NPDR) patients. The accumulation of these cytokines is believed to lead to 
early neuronal cell death. Cytokines such as MIP-1, IL-3 and IL-1 are believed to 
have a role in the angiogenesis. Thus inflammation may contribute towards and 
precede the development of neovascularisation [23]. Cylco-oxygenase-2 (COX-2) is 
expressed in the retinal astrocytes in human diabetic retinas. Prostanoids generated 
from COX-2 lead to an increased expression of VEGF and other pro-angiogenic fac-
tors, thereby contributing to development of proliferative diabetic retinopathy [24].
In case of diabetic macular edema (DME) levels of pro-inflammatory molecules 
Vascular Endothelial Growth Factor (VEGF) and IL-6 are noted to be elevated as 
per different studies. In particular DME associated with sub-retinal fluid on OCT 
shows elevated levels of these cytokines [25].
4.3 Diabetes and inflammation
The signal for the initiation of inflammation in a diabetic retina is believed to be 
metabolic in origin. Cell death was proposed as one of the causes, however, retinal 
cell death in DR is primarily via apoptosis and hence may not be associated with 
an inflammatory response. Certain factors that contribute directly or indirectly to 
increased inflammation are summarised below:
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4.3.1 Hyperglycemia
Presence of hyperglycemia is linked with a pro-inflammatory environment. 
Retinal cells when incubated in high glucose environment led to increased produc-
tion of iNOS, COX-2 and leukotrienes [26]. Furthermore, Joussen et al. in 2004 dem-
onstrated diabetic retinopathy like disease following a sugar rich diet in laboratory 
mice. This was associated with leukostasis and increased vascular permeability [27].
4.3.2 Oxidative stress
Diabetes is known to produce oxidative stress at a molecular level. Two months of 
diabetes in rats led to a significant increase in levels of IL-1 and NF-κB. This increase is 
inhibited by antioxidants. It is believed that oxidative stress induced increase in retinal 
permeability and inflammation is mediated via the WNT signalling pathway [28].
4.3.3 Lipids
Diabetes results in a decrease in the levels of poly-unsaturated fatty acids especially 
docosohexanoic acid (DHA) and these changes are associated with chronic inflam-
mation. Long term administration of omega 3 fatty acids has been linked to retinal 
capillary degeneration. DHA, resolvins and autocoids have shown to have critical anti-
inflammatory properties. Li et al. noted that administration of statins (HMG-CoA 
inhibitor) inhibited diabetes induced changes in the blood retinal barrier [29].
4.3.4 Age
Interaction between the advanced glycation end-products (AGE) with its recep-
tor (RAGE) is known to have pro-inflammatory consequences. Pharmacological 
inhibition of RAGE signalling led to a significant decrease in retinal capillary 
degeneration and other early lesion of DR in animal models [30].
4.3.5 Hypertension
Hypertension is a main secondary risk factor associated with DR. Silva et al. 
[31]. in 2007 found an increased expression of VEGF and ICAM-1 in an experi-
mental model in rats who were in a prehypertensive or hypertensive group. They 
concluded that hypertension led to an increased inflammatory response in the 
diabetic retina and consequently worsened retinopathy.
4.4 Inflammatory mediators involved
A variety of factors are involved in the cascade of the inflammatory process in 
a diabetic retina. It has been seen that intravitreal levels of cytokines, chemokines 
and growth factors change under inflammation leading to increased secretion from 
endothelial cell and development of neovascularization. The major factors are 
highlighted below:
4.4.1 Growth factors
4.4.1.1 Vascular endothelial growth factor (VEGF)
It is known that VEGF is the principal target of pharmacologic intervention 
for proliferative diabetic retinopathy and studies have confirmed elevated levels 
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of VEGF in vitreous samples in DR causing increased vascular permeability 
[32, 33], stimulates angiogenesis because of its mitogenic effect on endothelial 
cells, and enhances endothelial cell migration and survival [34, 35] and their 
production increases markedly under conditions of hypoxia [36]. Intercellular 
adhesion molecule-1 (ICAM-1) is involved in inflammation and acts as a local 
intensifying signal in the pathological processes associated with chronic eye 
inflammation. It has been seen that VEGF increases ICAM-1 and leukocyte 
adhesion to vessel wall and elevated ICAM-1 and cell adhesion molecule-1 syn-
thesis in retina. It further increases ICAM-1 in endothelial cells and this in turn 
leads to activation and increased production of cytokines and leukocyte activa-
tion [37], these cytokines initiate and mediate the inflammatory response and 
stimulate further release of VEGF [38]. Various studies have strongly indicated 
that the increased level of ICAM-1 generally exists in the patients with DR and 
it may associated with the severity of DR [39]. Placental growth factor (PGF), 
member of VEGF family, binds to VEGF- and neuropilin-receptor sub-types. 
PGF induces a range of neural, glial and vascular cell responses that are distinct 
from VEGF-A. As its expression is associated with pathological angiogenesis 
and inflammation, its blockade does not affect the healthy vasculature [40]. 
High levels of PGF have been found in aqueous humour, vitreous and in retina 
of patients especially those with diabetic retinopathy (DR). Results suggest that 
anti-PGF therapy might have advantages over anti-VEGF treatment, and that it 
may have clinical applications as a standalone treatment or in combination with 
anti-VEGF [40]. Low concentrations of VEGF have been seen to rise with PGF 
stimulating endothelial cell proliferation, migration, and angiogenesis [41]. 
Higher levels of PGF in vitreous are seen in DR and these levels are correlated 
well with VEGF levels [42].
4.4.1.2 Tenascin-C (TNC)
Tenascin-C is an extracellular matrix protein and plays an important role in cell 
growth and adhesion, playing an equally involved in angiogenesis, oncogenesis, 
wound repair and inlflammation [43, 44]. Studies have shown that TNC is involved 
in the pathogenesis of ischemic proliferative retinopathy. Elevated levels have been 
detected in PDR vitreous humour. mRNA and protein expression of TNC has been 
found in pre-retinal fibrovascular membranes excised from PDR patients [45]. 
Extracellular matrix (ECM) synthesis plays an important part in the pathogenesis of 
the intravitreal membranes and is thus characteristic of both proliferative vitreo-
retinopathy (PVR) and early stages of proliferative diabetic retinopathy (PDR). 
Hence it is clear that TNC plays a role in the development of epiretinal PVR and 
PDR membranes by controlling cell adhesion and regulating extracellular matrix 
formation formation [46].
4.4.1.3 Insulin like growth factor
It is known that IGF-1 is has a significant role in pathogenesis of DR as it is 
involved in regulation along with influencing growth, maturation and functioning 
of blood vessels. It also activates VEGF in human RPE cell and receptors which are 
actively involved in development of vitreo-retinal disorders [47, 48]. Insulin-like 
growth factor-I (IGF-I) is known to enhances insulin action in normal subjects and 
in both type 1 and 2 diabetes. It is associated with significant side effects in a high 
percentage of patients. Simultaneous administration of IGF binding protein-3 with 
IGF-I limits IGF-I inducible side effects, but it does not downgrade the ability of IGF-I 
to enhance protein synthesis and bone accretion [49]. Severity of DR in patients with 
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type 1 diabetes is inversely related to serum IGF-1 levels. Low IGF levels are an indica-
tor for closer follow-up and strict management of diabetes and retinopathy [50].
4.4.1.4 Basic fibroblast growth factor
Amongst the factors which play a role in mitogen and antigenic activity involv-
ing survival and maturation of glial cells and neuron, basic fibroblast growth factor 
(bFGF) play an important role [51]. Neurotrophic factors synthesised from glial 
cell line stimulates Muller cells which produce bFGF, which initiates endothelial cell 
proliferation and VEGF production [52, 53]. Studies have detected presence of two 
growth factors in same cells of ocular neovascular membrane suggesting more than 
one growth factor may contribute to defective angiogenesis. Growth factors are not 
exclusively seen in neovascular tissues and are not localised mainly in the vascular 
endothelium as shown by this study which detected their presence in choroidal 
neovascular membranes also [54]. Another study documented increased levels of 
basic fibroblast growth factor in vitreous specimens from patients with proliferative 
diabetic retinopathy, particularly those with active proliferative retinopathy [55]. 
Various studies have shown that bFGF, nerve growth factor, and glial cell line-
derived neurotrophic factor are also part of process involved in the formation of 
epiretinal membranes in PDR [56]. This confirms that both vegf and basic fibro-
blast growth factor are present in diabetic eyes and part of process causing PDR.
4.4.1.5 Aminopeptidase
Adipocytes are involved in production of a polypeptide hormone named 
aminopeptidase, which circulates at very high levels in the bloodstream, exerts 
anti-inflammatory effect. It also expresses an anti-atherosclerotic effect and 
inhibits intimal thickening and vascular smooth muscle cell proliferation in injured 
arteries [57]. Angiogenesis, a neo-vessel formation from pre-existing micro-vessels 
requires sequential steps involving detachment of pre-existing pericytes for 
vascular destabilisation, extracellular matrix turnover, migration, proliferation, 
tube formation by endothelial cells, and reattachment of pericytes for vascular 
stabilisation. Aminopeptidases has been found to regulate the N-terminal modi-
fication of proteins and peptides for maturation, activation or degradation, and 
thereby relate to a variety of biological processes. Three types of aminopeptidases 
which have been reported are involved in angiogenesis. They include type 2 
methionine aminopeptidase, aminopeptidase N, and adipocyte-derived leucine 
aminopeptidase/puromycin insensitive leucyl-specific aminopeptidase [58]. It has 
been documented and shown by Costagliola et al. [59]. that APN levels in aqueous 
humour of patients with type 2 diabetes, PDR, and macular edema are higher than 
in aqueous of control subjects.
4.4.1.6 Connective tissue growth factor
Connective tissue growth factor, also known as CCN2, is a cysteine-rich 
matricellular protein forms part of control on biological processes, such as cell 
proliferation, differentiation, adhesion and angiogenesis, as well as multiple 
pathologies, such as tumour development and tissue fibrosis [60]. Possible role of 
CTGF, CD105, and gelatinase B in the pathogenesis of proliferative vitreo-retinal 
disorders has been suggested by various studies [61]. It has been see that both 
CTGF and VEGF levels are elevated in PDR patients and CTGF could help in 
development of proliferative membranes in PDR though plays no role in retinal 
neovascularization [62].
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4.4.1.7 Hepatocyte growth factor
Its has been seen that HCG and its receptor unit control motility, growth and 
morphogenesis of various cell types and possess angiogenic activity [63]. Data indi-
cates that HGF is a pro-permeability, pro-inflammatory, and pro-angiogenic factor 
and along with its activator is found increased in ischemic retina providing support 
for a potential role of HGF in macular edema and in ischemic retinopathies such as 
diabetic retinopathy [64]. Elevated levels of HCG in aqueous have been found to be 
directly related to degree of PDR [65].
4.4.1.8 Stem cell factor
EPO is a glycoprotein which is multifunctional, produced in foetal liver 
and adult kidney when exposed to hypoxic conditions [66]. It possess anti-
inflammatory, antioxidant, pro-angiogenic properties [67–69]. Some studies have 
also documented neuro-protective and anti-apoptotic properties [70, 71]. The 
mechanisms controlling the expression of the gene encoding for the hormone 
erythropoietin (EPO) are exemplary for oxygen-regulated gene expression. 
In humans and other mammals, hypoxia modulates EPO levels by increasing 
expression of the EPO gene [72]. Expression of EPO is mediated by HIF-1α which 
simultaneously stimulates VEGF secretion [73]. The hormone erythropoietin 
(EPO) maintains red blood cell mass by promoting the survival, proliferation and 
differentiation of erythrocytic progenitors. Circulating EPO originates mainly 
from fibroblasts in the renal cortex. EPO production is controlled at the transcrip-
tional level. Hypoxia attenuates the inhibition of the EPO promoter by GATA-2 
[74]. In patients with PDR, both EPO and VEGF are up-regulated into the vitreous 
each acting independently [75]. It has been seen that inhibition of EPO or VEGF 
leads to suppression of retinal neovascularization, results are best when both are 
suppressed together and in vitro inhibition of EPO leads to attenuation of endo-
thelial cell proliferation in PDR [76].
4.4.2 Transcription factors
4.4.2.1 Nuclear factor kappa beta (NF-κB)
NF-κB is a pro inflammatory transcription factor and a regulator of inflamma-
tion related to immune responses, cellular proliferation and cell apoptosis [77]. It 
is located in endothelial and retinal pericytes and released on exposure to hypoxia 
and hyperglycemia and thereafter releases cytokines, chemokines, and other 
pro-inflammatory molecules [60]. Once NF-κB is activated it leads to production 
of cytokines, chemokines and other pro-inflammatory molecules [78]. Studies 
have shown a relation between NF-κB activation and downstream up-regulation of 
vascular endothelial growth factor (VEGF) in DR. VEGF SNPs i.e., RS2010963 C 
allele and RS3025039 T allele might be strongly associated with PDR occurrence and 
in turn regulating VEGF expression in PDR subjects [79]. NF-κB is also involved 
in the formation of both glial and vascular endothelial cellular components, and 
that these two cell types might have functional interactions that lead to the enlarge-
ment of intraocular proliferative membranes namely ERM [80]. Receptor activa-
tor of NF-κB ligand (RANKL) is a member of the tumour necrosis factor (TNF) 
superfamily. RANKL increases endothelial permeability and induces angiogenesis, 
suggesting its critical roles in the vasculature. Hence the use of an RANKL blockade 
as a potential therapeutic approach against ischemic retinopathies is confirmed 
[81]. It is important to remember that the signal related to RANKL plays a role in the 
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pathogenesis of insulin resistance and suggests a link between inflammation and 
the pathogenesis of type 2 diabetes mellitus [82].
4.4.2.2 Hypoxia inducible factor
Adapting to hypoxic conditions leads to cellular and tissue transcriptional 
induction involving genes that participate in angiogenesis, glucose metabolism, and 
cell proliferation and survival. The principal factor mediating this response is the 
hypoxia-inducible factor-1 (HIF-1), an oxygen-sensitive transcriptional activator. It 
consists of a constitutively expressed subunit HIF-1β and an oxygen-regulated sub-
unit HIF-1α [83]. It has been shown that diabetic factors result in HIF-1 production 
and angiogenesis and Treins et al. [84]. showed that insulin-like growth factor-1 
(IGF-1) stimulates accumulation of HIF-1 in human retinal pigment epithelial cells. 
As HIF-1 becomes active it activates several genes, including the genes for IL-6, 
IL-8, and pro-angiogenic growth factors. It has also been shown that acute intensive 
insulin therapy exacerbates the diabetic induced BRB breakdown through HIF-1 
and VEGF [85] and presence of HIF-1α has been demonstrated in diabetic epiretinal 
membrane [86]. NF-κB controls the expression and synthesis of HIF-1 in response 
to inflammatory stimuli. Hypoxia activates NF-κB that binds promoter of HIF-1, 
stimulates the production of IL-6 and IL-8 in the vitreous of patients with PDR. 
HIF-1α, Ang-2 and VEGF seem to play an important role in the pathogenesis of PDR 
and simultaneously provide adverse angiogenic milieu in PDR epiretinal mem-
branes favouring aberrant neovascularisation and endothelial abnormalities [85].
4.4.3 Cytokines
4.4.3.1 Interleukin-6 (IL-6)
IL-6 is a cytokine regulates the expression of matrix metalloproteinases (MMPs) 
which is a primary constituent of the vitreous [87, 88] and it also regulates immune 
response, increases permeability of vessels and initiates angiogenesis [89, 90]. 
Studies, have indicated that IL-8, VEGF-A, and PlGF demonstrated a strong cor-
relation in vitreous and aqueous of patients with PDR. The aqueous may serve as a 
proxy for vitreous for some cytokines involved in PDR. More recently anti-VEGF 
injections have been able to decrease VEGF-A levels in aqueous, however they did 
not significantly affect other cytokines, indicating a need for other targeted thera-
pies in PDR management [91]. Role of IL-6 in neovascularization, a key clinical 
feature of DR, is shown in studies that show IL-6 can not only promote angiogenesis 
directly but support angiogenesis by inducing expression of VEGF, an angiogenic 
factor [92]. Hence, the role of IL-6 and IL-8 as angiogenic and factor for causing 
neovascularization is supported.
4.4.3.2 IL-1β
Macrophages produce IL-1β which is an inflammatory cytokine mainly which 
can further activate the transcriptional factor NF-κB, which plays an important role 
in transcription of inflammatory cytokines [93]. Furthermore TNF-α and recom-
binant IL-1β seem to stimulate human retinal pigment epithelium cells leading to 
secretion of IL-6 and IL-8 [94]. It has been seen in studies that TNF-α and IL-1β 
promote angiogenic activity leading to stimulation and synthesis of collagen glial 
cells, and fibroblasts leading to proliferation and contraction promoting angio-
genesis and ocular neovascularization [95]. It has been observed that invading 
microorganisms activate the inflammatory response by secreting pro-inflammatory 
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cytokines particularly IL-1β. IL-1-responsive genes initiate and coordinate local 
inflammation and also attract and activate cells of the adaptive immune system at 
sites of infection eventually leading these signals to activate NALP3-inflammasome 
pathway, which plays a central role in acute and chronic sterile inflammation [96]. 
Studies assessing inflammatory mechanisms involving NLRP3 inflammasome were 
carried out using akimbo mouse, revealing an increased vascular leakage, reduced 
retinal thickness, and function in Akimba retina. High levels of IL-1β along with 
increased NLRP3, ASC, and Caspase-1 at mRNA and protein levels were seen 
suggesting a critical role for NLRP3 inflammasome in akimbo retina depicting 
advanced stages of DR pathogenesis [97]. Other studies have shown elevated levels 
in aqueous of IL-6 and macular thickness indicating IL-6 may play a central role in 
the development of diabetic macular edema [98].
4.4.3.3 TNF-alpha
TNF-α, a cytokine with tumour necrosis activity is produced by various types of 
cells which includes macrophages, is recognised as an important host defence factor 
that affects malignant and normal cells. It is synthesised by T cells and macrophages 
and its expression is regulated by NF-κB [99]. It also plays the role of inflammatory 
mediator of neuronal cell after cerebral ischemic trauma and also a similar role in 
retinal tissue [100]. Besides increasing endothelial cell permeability [101]. TNF-α 
is also involved in stimulating leukocyte adhesion and inducing oxidation and 
simultaneous production of reactive oxygen due to the death of retinal ganglion 
cells and degeneration of the optic nerve [102]. High pharmacological doses of 
TNF-α combined with chemotherapy has been seen to regress intractable tumours. 
Evidence demonstrates that pathophysiological concentrations of endogenous 
TNF-α could act to promote tumour genesis and growth [103]. In diabetic retinopa-
thy pro-inflammatory mediators regulated by cytokines, such as TNF-α, IL-1β and 
growth factors leads to further progression of these processes, leading to vaso-
permeability (diabetes macular edema) and/or pathological angiogenesis (prolif-
erative diabetic retinopathy) [104]. Diabetic patients have shown higher TNF-α 
levels in vitreous/serum ratio compared to non-diabetics [105]. Strong correlation 
between plasma TNF-α levels and severity of DR has been documented [106]. It has 
been documented that TNF-α is expressed in the endothelial cells and stromal cells 
of the fibrovascular membranes of diabetic patients with PDR [107]. Studies have 
confirmed the presence of vascular endothelial growth factor (VEGF) and TNF-α 
in epiretinal membranes in proliferative eye disease [108]. Recent studies assessing 
the impact of anti-TNF agents on intermediary metabolism suggest that TNF-α 
blockade could improve insulin resistance and lipid profiles in patients with chronic 
inflammatory disease [109].
4.4.3.4 HMGB1
HMGB1 though secreted from numerous sites in the retina, including the 
ganglion cell layer, inner nuclear layer, outer nuclear layer, inner and outer segment 
of the photoreceptors, and retinal pigment epithelial cells [110, 111]. It is a protein 
that stabilises the formation of nucleosomes and gene transcription [112]. Studies 
indicate that HMGB1 is released from activated innate immune cells or necrotic cells 
and functions as an important mediator of endotoxaemia, sepsis, arthritis, and local 
inflammation hence agents that inhibit HMGB1 release or action, confer significant 
protection against endotoxaemia, sepsis, and arthritis in animal models and thus 
hold potential for the clinical management of various inflammatory diseases [113]. 
HMGB1 functions as a cytokine that amplifies the effect of the receptor for AGE 
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(RAGE) axis and mediates the secretion of survival factors such as VEGF-A, to 
counteract the effects of oxidative stress. HMGB1 is thought to contribute to the 
accelerated micro and macro-vasculopathy seen in diabetes [114]. Its level has been 
detected on higher side in vitreous in patients with PDR and has been detected in 
endothelial and stromal cells of ERM in PDR patients [115].
4.4.4 Chemokines
Chemokines constitute a family of chemoattractant cytokines and are subdi-
vided into four families on the basis of the number and spacing of the conserved 
cysteine residues in the N-terminus of the protein. They seem to play a role in 
selectively recruiting monocytes, neutrophils, and lymphocytes, along with induc-
ing chemotaxis through the activation of G-protein-coupled receptors.
4.4.4.1 Monocyte chemoattractant protein-1 (MCP-1/CCL2)
Monocyte chemoattractant protein-1 (MCP-1/CCL2) is considered one of the 
key chemokines that regulate migration and infiltration of monocytes/macrophages 
[116]. The expression of MCP-1 is regulated by NF-κB and MCP-1 can induce VEGF 
production [117]. Both CCL2 and its receptor CCR2 have been demonstrated to be 
induced and involved in various diseases [116]. Diabetic patients have shown ele-
vated levels of MCP-1 in vitreous and its levels are higher in the vitreous than in the 
serum indicating local production of MCP-1 [118]. Studies have shown that there is 
a significant association between the vitreous MCP-1 levels and DR severity [119]. 
The MCP-1 is also a potent chemotactic factor for monocytes and macrophages that 
can stimulate them to produce superoxide and other mediators. Following hyper-
glycemia, retinal pigment epithelial (RPE) cells, endothelial cells, and Müller’s glial 
cells are of utmost importance for MCP-1 production, and vitreous MCP-1 levels 
rise in patients with DR. Increased expression of the MCP-1 in the eyes can also 
play a significant role in the pathogenesis of DR [120]. Interferon-gamma inducible 
protein 10 (IP-10) is a CXC chemokine that is expressed at higher levels in the vitre-
ous of diabetic patients [121], and its vitreous levels are higher than its serum levels 
[122]. Anti-inflammatory cytokines such as IL-10 and IL-13 may be involved more 
in the pathogenesis of DR and CRVO than in other diseases and both cytokines and 
chemokines may be correlated to VEGF in the vitreous fluid and the inflammatory 
reaction may be more active in CRVO than in DR [123].
4.4.4.2 Monokine
Monokine which is induced by interferon-gamma (MIG) is a chemoattrac-
tant for activated T cells and also has angiostatic activity [124]. In their study 
Wakabayashi et al. reported that MIG could play an role in the pathogenesis of DR 
and works in cooperation of VEGF in the progression of pathological angiogenesis 
in DR. The authors have detected higher levels of MIG in vitreous of DR patients 
[124]. Elevated MIG levels are could be in response to the up-regulation of angio-
genic factors such as VEGF. The alternative mechanism could be in play in DR 
which results in chemotaxis of leukocytes rather than in carrying out its angiostatic 
functions [27].
4.4.4.3 Stromal cell-derived factor-1
Stromal cell-derived factor-1 (SDF-1) is a chemokine that is up-regulated in 
response to tissue damage and is involved in stimulation and mobilisation of cells 
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involved in tissue repair and cellular migration, differentiation, and proliferation 
of endothelial progenitor cells [125]. SDF-1 repairs after ischemic injury by bind-
ing to its receptor, CXCR4 and recruits the progenitors of endothelial cells from 
the bone marrow. The levels off SDF-1 in vitreous have been found to be on higher 
side in DME and PDR patients [126]. Studies have demonstrated that inhibiting the 
N-(carboxymethyl)lysine-induced TPL2/ATF4/SDF1 axis can effectively prevent 
diabetes mellitus-mediated retinal microvascular dysfunction and this signalling 
axis could include the therapeutic potential for other diseases involving pathologi-
cal neovascularization and or macular edema [127].
4.4.4.4 Fractalkine
Fractalkine (CX3CL1) is an intriguing chemokine that plays a central role in the 
nervous system. Expression of CX3CL1 on neurons and its receptor CX3CR1 on 
microglia facilitates a privileged interaction, playing important roles in regulating 
the function and maturation of these cells. CX3CL1 is reported to have neuro-
protective and anti-inflammatory activities [128]. Studies suggest that dysregulated 
microglial activation via loss of FKN/CX3CR1 signalling disrupts the vascular 
integrity in retina during systemic inflammation [129].
4.4.4.5 Macrophage migration inhibitory factor
Macrophage migration inhibitory factor (MIF) is a chemokine that stimulates 
macrophages causing their recruitment at sites of inflammation, increasing their 
adherence, motility, and phagocytosis. It also prevents random migration of mac-
rophages [130]. Studies indicate increased levels of MIF in the vitreous of patients 
with PDR and a significant association between MIF levels and grades of fibrous 
proliferation, suggesting the possibility that MIF may play a part in the develop-
ment of the proliferative phase of PDR [131].
4.4.5 Intercellular adhesion molecule-1 (ICAM1)
ICAM-1 is a cell surface glycoprotein, which serves as an adhesion receptor that 
is known for regulating leukocyte recruitment from circulation to sites of inflam-
mation. In addition to vascular endothelial cells, ICAM-1 expression is also induced 
on epithelial and immune cells in response to inflammatory stimulation. ICAM-1 
also serves as a biosensor to transduce outside-in-signalling via association of its 
cytoplasmic domain with the actin cytoskeleton following ligand engagement of 
the extracellular domain. Thus, ICAM-1 has emerged as a master regulator of many 
essential cellular functions both at the onset and at the resolution of pathologic 
conditions [132]. Increased expression of adhesion molecule leads to activation of 
RAGE, oxidative stress, vascular leakage in the diabetic retina, capillary non perfu-
sion, and damage of endothelial cells and the adhesion of leukocytes to the endo-
thelium and expression of retinal vascular adhesion molecules such as VEGF [133]. 
ICAM-1 is the primary adhesion molecule involved in DR and its levels in vitreous 
are elevated in patients with active PDR [115].
5. Therapy aimed at inflammatory targets
Maintenance of a good glycemic control is considered to be the most important 
modifiable factor influencing the stage and progression of diabetic retinopa-
thy. However, inhibition of retinal inflammation may also reduce the degree of 
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retinopathy despite the presence of a hyperglycaemic state. High-dose aspirin, 
COX-2 inhibitors and corticosteroids have been used, either experimentally in 
animal models or therapeutically in humans, and found to have a beneficial effect 
in reducing DR changes. However, these drugs are associated with unfavourable 
side effects especially when used over a long-term course. Hence other alternatives 
should be looked at. These alternatives can include RAGE inhibitors, minocycline, 
derivatives of salicylates and inhibitors of TNF-α and 5-lipoxygenase. Salicylates 
inhibit the nuclear migration and possibly activation of NF-κB in retinal neurons 
[134]. Evidence is accumulating showing that lipid supplementation with omega 3 
polyunsaturated fatty acids (especially DHA) has a beneficial effect in DR [135].
Retinal inflammatory changes in diabetics have been found to be inhibited by 
therapies wherein the primary target is at a different site. The antihypertensive 
telmisartan, angiotensin receptor blocker (Type I receptor) was found to sup-
press retinal leukostasis and expression of VEGF and ICAM-1 [136]. Similarly, 
in diabetic animal models, Candesartan reduces the presence of acellular retinal 
capillaries, iNOS and nitric oxide [137]. The beneficial effect of statins on DR has 
also been reported by Kang et al. in 2019 [138]. The authors evaluated patients with 
diabetes and dyslipidemia and found that statin use was associated with a decreased 
prevalence of DR and a lower need for invasive therapy for vision threatening 
diabetic retinopathy complications. This therapeutic benefit can be attributed to the 
pleiotropic property of statins, which also function as anti-inflammatory agents. 
Tuuminen et al. [139] found a decreased intravitreal levels of pro-angiogenic fac-
tors, transforming growth factor B1 and matrix metalloproteinase 9 in individuals 
treated with simvastatin.
The role of salicylates in DR has been studied extensively, following the initial 
reports by Powell and Field in 1964 [21]. Administration of aspirin in animal 
models has found to reduce retinal capillary degeneration but conflicting results 
were reported in human trials. The Early Treatment Diabetic Retinopathy Study 
(ETDRS) is particularly of note in this case. The ETDRS report number 8 results 
indicated that aspirin has no clinically beneficial effect on the progression of 
retinopathy in individuals taking 650 mg of aspirin per day [140]. However, we 
have to take into account that the anti-inflammatory dose of aspirin is much higher 
than what was being administered in the study. Salicylates have shown to reduce 
insulin resistance in the retina in a Type II diabetic rat model as per Jiang Y and 
co-workers [141].
TNF-α is a key molecule in the inflammatory puzzle thus it serves as an attrac-
tive pharmacological target. Subcutaneous injection of TNF-α trap (Eternacept) 
was found to significantly reduce retinal inflammation, retinal cell injury and vas-
cular permeability in diabetic rats [142]. However, no clinical trials have reported 
this effect till date. A small pilot study of 4 patients who were administered 
Infliximab (TNF-α antibody) showed a decrease in central macular thickness and a 
corresponding improvement in visual acuity [143].
Inhibition of leukostasis is another mechanism that can be targeted in anti-
inflammatory therapy for DR. Leukocyte function associated antigen-1 (LFA-1) 
is an integrin molecule and is extremely important for leukocyte-endothelial 
cell interactions. SAR-1118 is a topical antagonist of LFA-1 and has shown a dose 
dependant reduction of leukostasis and vascular leakage in a diabetic rat model 
[144]. Anti CD49a neutralising antibody blocks the interaction between very 
late antigen-4 (VLA-4) and VCAM-1 and has also shows efficacy in reducing 
leukostasis [145].
Apart from their antibiotic activity both Minocycline and Doxycycline are 
known to possess neuro-protective and immunomodulatory properties, such as 
inhibiting production of NO, prostaglandins, TNF-α and caspases [146]. A small 
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study of minocycline in 5 patients with DME showed improvement in visual acuity 
with reduction in macular edema [147]. Another study involving doxycycline 
demonstrated an improvement in perimetric parameters in individuals with severe 
NPDR or PDR [148].
Photobiomodulation is another prospective therapy which has shown promise in 
a small clinical study of patient with non-centre involving diabetic macular edema 
[149]. It consists of series of brief illumination with specific wavelengths of light 
emitted from a laser. It has shown to affect the signalling pathways within the cells 
and inhibits diabetes induced leukostasis, ICAM-1 expression and production of 
reactive oxygen species [150].
6. Conclusion
Studies carried out both in diabetic patients and experimental animal models 
of diabetic retina have shown that the diabetic milieu promotes an increased local 
expression of inflammation. Unlike, uveitis however this inflammation is not 
clinically apparent and is noted at a molecular level. Critically located between the 
vasculature and neurons of the retina, Glial cells have a key role in closely regulat-
ing the retinal microenvironment. Recent findings implicate that these cells also 
responsible in the initiation of the inflammatory cascade.
It is possible that inflammation does not perfectly describe all the changes that 
ultimately occur in diabetic retinopathy, but it does seems to describe the pathogen-
esis of the retinopathy better than the previous concept of microvasculopathy. It is 
likely that this concept will become better focused with future research.
© 2021 The Author(s). Licensee IntechOpen. This chapter is distributed under the terms 
of the Creative Commons Attribution License (http://creativecommons.org/licenses/
by/3.0), which permits unrestricted use, distribution, and reproduction in any medium, 
provided the original work is properly cited. 
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